Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.

Abstract

BACKGROUND:

Ovarian cancer is a serious threat to women's health, and resistance to chemotherapeutic drugs constitutes one of the principal reasons for ovarian cancer recurrence and the low overall survival rate. Therefore, it is of paramount importance to develop additional and more-effective drugs to combat resistance to chemotherapeutic drugs. Cucurbitacin B (CuB) is a natural compound found in food plants such as bitter gourd and pumpkin, and it manifests favorable antitumor effects on a variety of malignant tumors.

PURPOSE:

The present study aimed to determine the mechanism effects of CuB overcomes tumor-drug resistance in ovarian cancer.

METHODS:

We used CCK-8, Edu, flow cytometric assays and cisplatin-resistant ovarian cancer xenograft mouse model to evaluate the cellular proliferation, cellular apoptosis.and tumor growth. We subsequently applied a pharmacoproteomic approach to analyze the molecular mechanisms by which CuB inhibited the proliferation of cisplatin-resistant ovarian cancer cells. We also employed western blot and molecular docking experiments to verify elements of PI3K/Akt/mTOR pathway expression.

RESULTS:

We found that CuB inhibited cellular proliferation and promoted apoptosis in cisplatin-resistant ovarian cancer cell lines. We discerned that CuB inhibited tumor growth of xenograft mouse tumors. We ascertained that treatment of A2780-DDP cells with CuB resulted in the differential expression of 305 proteins, with 202 proteins downregulated and 103 proteins upregulated. Of these proteins, the mTOR protein was significantly downregulated in the drug-treated group. We also found that CuB inhibited PI3K, Akt, and mTOR and that it activated cGAS expression upstream of PI3K and inhibited ATR expression. Molecular docking experiments revealed that CuB was hydrogen-bonded to mTOR proteins at Gly (2142) and Thr (2207), with a binding force of -10.2 kcal/mol.

CONCLUSION:

Our study confirmed that cucurbitacin B inhibits the PI3K/Akt/mTOR signaling pathway, targets mTOR, suppresses the proliferation of cisplatin-resistant ovarian cancer cells.And we also found that cucurbitacin B induces DNA damage, activates cGASA and recruits IKBα,playing a crucial role in eliciting anti-tumor immunity. We herein uncovered a new use for CuB in inhibiting tumor-drug resistance, providing a novel approach to overcoming chemotherapeutic drug resistance in ovarian cancer.

• Authors: Shuanghong Yin, Zhikai Mai, Can Liu, Lipeng Xu, Chenglai Xia
• Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology (Phytomedicine) Vol. 111 Pg. 154669 (Mar 2023) ISSN: 1618-095X [Electronic] Germany
• PMID: 36681055 (Publication Type: Journal Article)
• Copyright: Copyright © 2023 Elsevier GmbH. All rights reserved.

Chemical References

• Cisplatin
• cucurbitacin B
• Proto-Oncogene Proteins c-akt
• Phosphatidylinositol 3-Kinases
• TOR Serine-Threonine Kinases

Topics

• Humans
• Female
• Animals
• Mice
• Cisplatin (pharmacology, therapeutic use)
• Ovarian Neoplasms (drug therapy, pathology)
• Proto-Oncogene Proteins c-akt (metabolism)
• Cell Line, Tumor
• Phosphatidylinositol 3-Kinases (metabolism)
• Molecular Docking Simulation
• Proteomics
• Neoplasm Recurrence, Local
• TOR Serine-Threonine Kinases (metabolism)
• Drug Resistance, Neoplasm
• Cell Proliferation
• Apoptosis